Essential medicines for pediatric oncology in developing countries
- 28 February 2013
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 60 (5), 889-891
- https://doi.org/10.1002/pbc.24476
Abstract
The burden of cancer in children in low and middle income countries (LMICs) is substantial, comprising at least 80% of incident cases globally, and an even higher proportion of cancer-related deaths. With survival rates exceeding 80% in high income countries, it is imperative to transfer these successes to LMICs. A major challenge is the poor availability of safe, cost-effective chemotherapy. A list of 51 drugs—chemotherapeutics, infectious disease agents, and supportive care medications—is proposed as essential to improving the survival of children with cancer in LMICs with an additional 13 drugs identified as being of further value. Pediatr Blood Cancer 2013; 60: 889–891.Keywords
This publication has 23 references indexed in Scilit:
- A prospective, randomized study of empirical antifungal therapy for the treatment of chemotherapy‐induced febrile neutropenia in childrenBritish Journal of Haematology, 2012
- Outcome of Acute Promyelocytic Leukemia (APL) in Children and Adolescents: An Analysis in Two Consecutive Trials of the European APL GroupJournal of Clinical Oncology, 2012
- A Comparative Efficacy of Amitriptyline, Gabapentin, and Pregabalin in Neuropathic Cancer PainAmerican Journal of Hospice and Palliative Medicine®, 2011
- Successful treatment of metastatic retinoblastoma with high-dose chemotherapy and autologous stem cell rescue in South AmericaBone Marrow Transplantation, 2011
- Voriconazole as primary antifungal prophylaxis in children undergoing allo-SCTBone Marrow Transplantation, 2011
- The Zambia Children's KS-HHV8 Study: Rationale, Study Design, and Study MethodsAmerican Journal of Epidemiology, 2011
- Phase II Study of Weekly Gemcitabine and Vinorelbine for Children With Recurrent or Refractory Hodgkin's Disease: A Children's Oncology Group ReportJournal of Clinical Oncology, 2009
- Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group StudyJournal of Clinical Oncology, 2009
- Global child health priorities: What role for paediatric oncologists?European Journal Of Cancer, 2008
- Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcomaCancer, 2005